eCite Digital Repository

Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence

Citation

Hussain, S and Singh, A and Baxi, H and Taylor, B and Burgess, J and Antony, B, Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence, Neurological Sciences pp. 1-7. ISSN 1590-1874 (2020) [Refereed Article]

Copyright Statement

Copyright 2020 Fondazione SocietÓ Italiana di Neurologia

DOI: doi:10.1007/s10072-020-04494-3

Abstract

Background: The thiazolidinedione (TZD) class of oral antidiabetic agents are used to treat type 2 diabetes mellitus (DM). This meta-analysis aimed to understand the protective effect of TZD on Parkinson's disease (PD) in people with diabetes.

Method: A literature search was performed in PubMed, Embase, and Cochrane central from inception to until 30 September 2019. We included all real-world evidence studies assessing the use of TZD class of drugs and the risk of PD in people with diabetes. Quality of the studies was evaluated using the Newcastle-Ottawa scale. The primary outcome was the pooled hazard ratio (HR) of PD among type 2 DM TZD users as compared with TZD non-users in people with diabetes. The secondary outcome was the HR of PD among type 2 DM TZD users as compared with non-users (include both diabetic and nondiabetic population). Meta-analysis was performed using RevMan software.

Results: Out of five studies selected for inclusion, four studies fulfilled the criteria for primary outcomes. The participants' mean age and follow-up duration were 66.23 ▒ 9.59 years and 5.25 years (2.97-7.9 years), respectively. There was a significant reduction in the risk of PD (pooled adjusted HR of 0.81 [95% CI 0.70-0.93, p = 0.004]) in TZD users compared with non-TZD users in people with diabetes. A significant protective effect of TZD was observed in Caucasian population (3 studies) (HR 0.78 (95% CI 0.66-0.92), p = 0.003).

Conclusion: This meta-analysis demonstrates a potential neuroprotective effect of TZD for PD risk in the population with DM.

Item Details

Item Type:Refereed Article
Keywords:diabetes mellitus, glitazone, Parkinson's disease, pioglitazone, thiazolidinedione's, meta-analysis
Research Division:Biomedical and Clinical Sciences
Research Group:Neurosciences
Research Field:Neurology and neuromuscular diseases
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Singh, A (Mr Ambrish Singh)
UTAS Author:Taylor, B (Professor Bruce Taylor)
UTAS Author:Burgess, J (Professor John Burgess)
UTAS Author:Antony, B (Dr Benny Eathakkattu Antony)
ID Code:139917
Year Published:2020
Web of Science® Times Cited:1
Deposited By:Menzies Institute for Medical Research
Deposited On:2020-07-15
Last Modified:2020-08-17
Downloads:0

Repository Staff Only: item control page